文献速递母胎医学产科

Ⅰ期双胎输血综合征伴间歇性脐动脉多普勒异常

Stage I twin-twin transfusion syndrome with intermittent umbilical artery Doppler abnormalities.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-08-15

该研究比较了2006至2023年接受激光手术的349例双胎输血综合征孕妇中,Ⅰ期供血儿脐动脉血流正常、Ⅰ期供血儿脐动脉间歇性舒张末期血流缺失或反向、Ⅲ期供血儿脐动脉持续性舒张末期血流缺失或反向三组的结局。Ⅰ期间歇性组供血儿宫内死亡风险高于Ⅰ期正常组,动脉-动脉吻合在该组更常见。

要点

  • Ⅰ期间歇性脐动脉异常者供血儿宫内死亡率25.0%,高于Ⅰ期正常者的3.0%。
  • Ⅰ期间歇性组动脉-动脉吻合率69.4%,高于Ⅰ期正常组的27.7%和Ⅲ期组的42.5%。
  • 多因素模型中Ⅰ期间歇性组供血儿宫内死亡OR为7.23,Ⅲ期组OR为7.24。

核心结论

  • Ⅰ期双胎输血综合征伴供血儿脐动脉间歇性舒张末期血流缺失或反向者,激光术后供血儿宫内死亡风险增加。

研究设计与样本

  • 对2006至2023年接受激光手术的349例单绒毛膜双羊膜囊双胎输血综合征患者进行三组分析:Ⅰ期术前供血儿脐动脉血流正常101例、Ⅰ期术前供血儿脐动脉间歇性舒张末期血流缺失或反向36例、Ⅲ期术前供血儿脐动脉持续性舒张末期血流缺失或反向212例。
  • 主要结局为供血儿宫内死亡。
  • 因动脉-动脉吻合与术后供血儿死亡相关,同时评估三组中该血管吻合的发生率。

主要发现

  • 供血儿宫内死亡率在Ⅰ期正常组为3.0%,Ⅰ期间歇性组为25.0%,Ⅲ期组为29.2%,P<.0001。
  • 至少一胎存活在三组间无差异;双胎存活率Ⅰ期正常组为97.0%,Ⅰ期间歇性组为75.0%,Ⅲ期组为66.0%,P<.0001,Ⅰ期正常组与Ⅰ期间歇性组及Ⅲ期组的两两比较均有差异。
  • 动脉-动脉吻合率Ⅰ期正常组为27.7%,Ⅰ期间歇性组为69.4%,Ⅲ期组为42.5%,P<.0001。
  • 多因素logistic回归模型中,与Ⅰ期正常组相比,Ⅰ期间歇性组供血儿宫内死亡的OR为7.23(95%CI 1.69-30.82),P=.0075;Ⅲ期组OR为7.24(95%CI 2.06-25.47),P=.0020。
  • 同一模型中,存在动脉-动脉吻合者供血儿宫内死亡的OR为3.59(95%CI 1.95-6.61),P<.0001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Twin-to-twin transfusion syndrome (TTTS) is a rare condition that occurs in approximately 9% to 15% of monochorionic diamniotic twin pregnancies. The Quintero staging system was established to categorize the severity of this disease. Published outcomes for selective laser photocoagulation of communicating vessels demonstrate a significant difference in dual survival outcomes among the different stages of TTTS. Per Quintero staging, Stage I TTTS includes those with donor twin umbilical artery (UA) intermittent, absent, or reversed end diastolic velocity (AREDV), whereas patients with persistent donor twin UA-AREDV are classified as Stage III. This distinction between intermittent and persistent UA-AREDV appears to have been variably interpreted since the original publication. OBJECTIVE: Our objective was to compare laser-treatment outcomes in Stage I patients with intermittent UA-AREDV vs Stage I patients with a normal UA waveform; Stage III patients with persistent donor twin UA-AREDV were used for comparison. Because arterio-arterial communications (AA) have been associated with postoperative donor demise, the rate of such vascular communications was also assessed within the 3 groups. STUDY DESIGN: Three groups of monochorionic diamniotic twins with TTTS that was treated with laser surgery (2006-2023) were analyzed for the primary outcome of donor twin intrauterine fetal demise (IUFD): Stage I with preoperative normal donor UA flow (Stage-I Normal); Stage I with preoperative intermittent donor UA-AREDV (Stage-I Intermittent); and Stage III with preoperative persistent donor UA-AREDV (Stage-III). RESULTS: Of 349 study patients, 101 were classified as Stage-I Normal, 36 were Stage-I Intermittent, and 212 were Stage-III. The rate of donor IUFD was lowest in Stage-I Normal vs Stage-I Intermittent and Stage-III groups: 3.0% vs 25.0% vs 29.2%, P<.0001. At least one survival did not differ among the 3 groups; dual survival was highest for Stage-1-Normal (97.0% vs 75.0% vs 66.0%, P<.0001) and differed from both Stage-I Intermittent and Stage-III groups in pairwise comparisons. AA communications were most common in the Stage-I Intermittent group: 27.7% vs 69.4% vs 42.5%, P<.0001. In a multiple logistic regression model, Stage-I Intermittent patients were 7 times more likely to have donor twin IUFD (Odds ratio [OR] 7.23 [1.69-30.82], P=.0075), as were Stage-III patients (OR 7.24 [2.06-25.47], P=.0020), compared to Stage-I Normal patients. In this same model, independently, patients with AA were 3.6 times more likely to have donor IUFD (OR 3.59 [1.95-6.61]; P<.0001). CONCLUSION: TTTS Stage I patients with intermittent UA-AREDV were at increased risk of donor IUFD after laser surgery.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Sun RC, Chon AH, Llanes A, et al. Stage I twin-twin transfusion syndrome with intermittent umbilical artery Doppler abnormalities. Am J Obstet Gynecol MFM. 2025. PMID: 40818504. doi:10.1016/j.ajogmf.2025.101754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。